Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson
Baxter
Dow
McKinsey

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Litigation Details for SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (D.N.J. 2017)


Email this page to a colleague

« Back to Dashboard

SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (D.N.J. 2017)

Docket ⤷  Try it Free Date Filed 2017-07-06
Court District Court, D. New Jersey Date Terminated
Cause 15:1126 Patent Infringement Assigned To Claire Claudia Cecchi
Jury Demand Plaintiff Referred To Mark Falk
Parties PRINSTON PHARMACEUTICAL, INC.; SOLCO HEALTHCARE U.S., LLC
Patents 10,030,060; 6,063,927; 6,080,759; 6,113,944; 6,172,233; 7,598,271; 8,658,663; 8,946,251; 9,375,388; 9,393,237
Attorneys JOHN COLEMAN LIFLAND; ROBERT JOSEPH FETTWEIS
Firms Jams
Link to Docket External link to docket
Small Molecule Drugs cited in SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC.
The small molecule drugs covered by the patents cited in this case are ⤷  Try it Free , ⤷  Try it Free , ⤷  Try it Free , and ⤷  Try it Free .
Biologic Drugs cited in SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC.
The biologic drugs covered by the patents cited in this case are ⤷  Try it Free and ⤷  Try it Free .

Details for SEBELA INTERNATIONAL LIMITED v. PRINSTON PHARMACEUTICAL, INC. (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-07-06 1 Label (April 2017), # 2 Exhibit B: U.S. Patent No. 9,393,237, # 3 Exhibit C: Actavis ANDA Approved Labeling… 6 July 2017 2:17-cv-04964 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff External link to document
2017-07-08 10 U.S. Patent No. 9,393,237, # 4 Exhibit 3: U.S. Patent No. 8,658,663, # 5 Exhibit 4: U.S. Patent No. 8,946,251… 6 July 2017 2:17-cv-04964 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff External link to document
2017-07-10 11 HOLDER or l'ATENT OR TRADEMARK. I us 9,393,237 7/19/2016 … ~ 0 Trademarks or ~Patents. ( O the patent action involves 35 U.S.C. § 292.): DOCKET… AO120 Patent Form filed. (jr) (Entered: 07/10/2017) 10 July 2017 PACER Document … REPORT ON THE Director of the U.S. Patent and Trademark Office … ACTION REGARDING A PATENT OR Alexandria, VA 22313 External link to document
2017-07-20 22 and administered at 0.01, 1.0, 10, 30 60 mg/kg) or 1-[1-(3-chlorophenyl)-2-(4-methyl- …fluoxetine (Sigma, dissolved in sterile H20 at 10, 30, 60 mg/kg) or combination of fluoxetine ·administered…in sterile H2 0 and administered at 1.0, 10, 30, 60 mg/kg) 1 hour prior to naloxone. Venlafaxine …dissolved in sterile H20 and administered at 1.0, 10, 30, 60 mg/kg), S- enantiomer of .oov …dissolved in sterile H20 and administered at 1.0, 10, 30, 60 mg/kg), or paroxetine (which was synthesized External link to document
2017-07-25 26 U.S. Patent No. 5,955,475, # 3 Exhibit 35: U.S. Patent No. 6,113,944, # 4 Exhibit 36: U.S. Patent No. …6,645,523, # 5 Exhibit 37: U.S. Patent No. 6,660,298, # 6 Exhibit 38: U.S. Patent No. 6,699,882, # 7 Exhibit…40: U.S. Patent Application Publication No. 2004/0067254 (Lemmens), # 9 Exhibit 41: U.S. Patent No. 6,369,051… 6 July 2017 2:17-cv-04964 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff External link to document
2017-10-02 50 A: Brisdelle Label, # 2 Exhibit B: U.S. Patent No. 9,393,237, # 3 Exhibit C: Prinston ANDA Approval Letter… 6 July 2017 2:17-cv-04964 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff External link to document
2017-10-20 60 Case No. 17-4964 (the “‘447 patent”) and 7,598,271 (the “‘271 patent”), were also asserted in the Prior…this Court: U.S. Patent Nos. 8,658,663 (the “‘663 patent”) and 8,946,251 (the “‘251 patent”). All three …237 patent is identical to those of the ‘663 and ‘251 patents. The ‘663 and ‘251 patents are… the ‘237 patent is very similar to claim I of the ‘251 patent. Claim 1 of the ‘251 patent recites: …would infringe the claims of U.S. Patent No. 9,393,237 (the “‘237 patent”),’ For the reasons set forth below External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Boehringer Ingelheim
McKinsey
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.